BPTS Up 73.13% After Study
Shows 44% Reduction In Risk
Of Respiratory Failure In
Severe Covid 19 Patients.
Biophytis (NASDAQ:BPTS) saw a huge close up 73.13% today after releasing pre-market news showing positive final results of the phase 2-3 COVA study with Sarconeos (BIO101) in severe COVID-19 patients. The results of the study showed a 44% significant reduction in the risk of resp…
Original source: http://www.pennystockdream.com/blog/bpts-up-7313-after-study-shows-44-reduction-in-risk-of-respiratory-failure-to-severe-covid-19-patients
